Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-375-5 | CAS number: 81-77-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP and OECD guideline compliant study with well characterized material.
Cross-reference
- Reason / purpose for cross-reference:
- reference to same study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 012
- Report date:
- 2012
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- Experimental Toxicology and Ecology, BASF SE, Ludwigshafen, Germany
- Limit test:
- no
Test material
- Reference substance name:
- 6,15-dihydroanthrazine-5,9,14,18-tetrone
- EC Number:
- 201-375-5
- EC Name:
- 6,15-dihydroanthrazine-5,9,14,18-tetrone
- Cas Number:
- 81-77-6
- Molecular formula:
- C28H14N2O4
- IUPAC Name:
- 6,15-dihydroanthrazine-5,9,14,18-tetrone
- Test material form:
- solid: nanoform, no surface treatment
- Details on test material:
- Batch: P 112045
Appearance: violet/dark blue solid
stable at room temperature
Purity according to elementary analysis: 100.2g/100g
Water content 0.24 g/100g
BET = 36.4m2/g
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS- Source: Charles River Laboratories, Research Models and Services, Germany GmbH - Age at study initiation: 10 - 12 weeks (males/females)- Weight at study initiation: mean(males): 304 g; mean(females): 201 g- Housing: individually in Makrolon type M III cages supplied by Becker & Co., Castrop-Rauxel, Germany, with the following exceptions: During overnight matings, male and female mating partners were housed together in Makrolon type M III cages, pregnant animals and their litters were housed together until PND 4 (end of lactation) with nesting material, for motor activity (MA) measurements the animals were housed individually in polycarbonate cages supplied by TECNIPLAST, Hohenpeißenberg, Germany and small amounts of bedding material.- Diet: Ground Kliba maintenance diet mouse-rat “GLP”, meal, supplied by Provimi Kliba SA, Kaiseraugst, Switzerland; ad libitum- Water:drinking water (from water bottles); ad libitum- Acclimation period: 6 daysENVIRONMENTAL CONDITIONS- Temperature (°C): 20 - 24°C - Humidity (%): 30 - 70% - Air changes (per hr): 15/hr- Photoperiod (hrs dark / hrs light): 12 / 12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:Blue CAS 81-77-6 was applied as a suspension. To prepare this suspension, the appropriate amount of test substance was weighed out depending on the desired concentration. Then, drinking water was filled up to the desired volume, subsequently released with a high speed homogenizer. During administration of the test substance, preparations were kept homogeneous by stirring with a magnetic stirrer. The test substance preparations were produced at least once a week. The administration volume was 10 mL/kg body weight.VEHICLE- Concentration in vehicle: 1 (100 mg/kg bw), 3 (300 mg/kg bw), 10 g/100 mL (1000 mg/kg bw)
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The analyses confirmed the stability of the test substance in drinking water at room temperature over a period of 7 days, the homogeneous distribution of the test substance in drinking water, and the correctness of the prepared concentrations of the test substance preparations in drinking water (the values were in the expected range of the target concentrations, i.e. were always in a range of about 102-109% of the nominal concentrations).
- Duration of treatment / exposure:
- The duration of treatment covered a 2-week pre-mating and mating period in both sexes, approximately 1 week post-mating in males, and the entire gestation period as well as 4 days of lactation in females followed by an additional treatment until one day before sacrifice (males: 34 / 35 days; females: 49 days)
- Frequency of treatment:
- daily
Doses / concentrations
- Remarks:
- Doses / Concentrations:100, 300 and 1000 mg/kg bwBasis:actual ingested
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes- Time schedule: A check for moribund and dead animals was made twice daily on working days and once daily on Saturdays, Sundays and public holidays. If animals were in a moribund state, they were sacrificed and necropsied. A cageside examination was conducted at least once daily for any signs of morbidity, pertinent behavioral changes and signs of overt toxicity. Abnormalities and changes were documented daily for each affected animal.DETAILED CLINICAL OBSERVATIONS: Yes - Time schedule: Before initial test substance administration and thereafter at weekly intervals.BODY WEIGHT: Yes - Time schedule for examinations: Body weights of F0 parents were determined on study day 0 (start of the administration period) and thereafter once a week, in males throughout the study and in females during premating and mating. During gestation and lactation period, F0 females were weighed on gestation days (GD) 0, 7, 14 and 20, after the day of parturition (postnatal day [PND] 0) and on PND 4.FOOD CONSUMPTION AND COMPOUND INTAKE:- Food consumption for each animal determined and mean daily diet consumption calculated as g food/animal/day: Yes - Compound intake calculated as time-weighted averages from the consumption and body weight gain data: NoFOOD EFFICIENCY:- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: NoOPHTHALMOSCOPIC EXAMINATION: No HAEMATOLOGY: Yes - Time schedule for collection of blood: towards the end of the administration period- Anaesthetic used for blood collection: Yes (isoflurane (Isoba®, Essex GmbH Munich, Germany)) - Animals fasted: Yes - How many animals: 5 animals per sex and group- Parameters checked: Leukocyte count (WBC), Erythrocyte count (RBC), Hemoglobin (HGB), Hematocrit (HCT), Mean corpuscular volume (MCV), Mean corpuscular hemoglobin (MCH), Mean corpuscular hemoglobin concentration (MCHC), Platelet count (PLT), Differential blood count, Reticulocytes, Prothrombin time (Hepato Quick’s test; HQT);CLINICAL CHEMISTRY: Yes - Time schedule for collection of blood: towards the end of the administration period- Animals fasted: Yes- How many animals: 5 animals per sex and group- Parameters checked: Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP), gamma-Glutamyltransferase (GGT), Sodium (NA), Potassium (K), Chloride (CL), Inorganic phosphate (INP), Calcium (CA), Urea (UREA), Creatinine (CREA), Glucose (GLUC), Total bilirubin (TBIL), Total protein (TPROT), Albumin (ALB), Globulins (GLOB), Triglycerides (TRIG), Cholesterol (CHOL), Magnesium (MG);URINALYSIS: Yes - Time schedule for collection of urine: 5 animals per sex and group towards the end of the administration period- Metabolism cages used for collection of urine: Yes - Animals fasted: Yes - Parameters checked: pH, Protein, Glucose, Ketones, Urobilinogen, Bilirubin, Blood, Specific gravity, Sediment, Color / Turbidity, VolumeNEUROBEHAVIOURAL EXAMINATION: Yes - Time schedule for examinations: Towards the end of the administration period - Dose groups that were examined: 5 animals per sex and test group.- Battery of functions tested: passive observations without disturbing the animals, followed by removal from the home cage, open field observations in a standard arena and sensorimotor tests as well as reflex tests, motor activityOTHER: Reproduction data and pup observation (See chapter "Toxicity to reproduction")
- Sacrifice and pathology:
- GROSS PATHOLOGY: YesHISTOPATHOLOGY: YesWeight assessment was carried out on all animals. The following weights were determined:Adrenal glands, Anesthetized animals, Brain, Epididymides, Heart, Kidneys, Liver, Testes, Spleen, ThymusThe following organs / tissues were preserved in neutral-buffered 4% formaldehyde or in modified Davidson’s solution:Adrenal glands, All gross lesions, Aorta, Bone marrow (femur), Brain, Cecum, Cervix, Coagulating glands, Colon, Duodenum, Eyes with optic nerve (modified Davidson’s solution), Esophagus, Extraorbital lacrimal gland, Epididymides (modified Davidson’s solution), Female mammary gland, Femur with knee joint, Heart, Ileum, Jejunum (with Peyer’s patches), Kidneys, Larynx, Liver, Lungs, Lymph nodes (axillary and mesenteric), Mammary gland (male and female), Nose (nasal cavity), Ovaries (modified Davidson’s solution), Oviducts, Pancreas, Parathyroid glands, Pharynx, Pituitary gland, Prostate gland, Rectum, Salivary glands (mandibular and sublingual), Sciatic nerve, Seminal vesicles, Skeletal muscle, Spinal cord (cervical, thoracic and lumbar cord), Spleen, Sternum with marrow, Stomach (forestomach and glandular stomach), Target organs, Testes (modified Davidson’s solution), Thymus, Thyroid glands, Trachea, Urinary bladder, Uterus, Vagina;From the liver, each one slices of the lobus dexter medialis and the lobus sinister lateralis were fixed in Carnoy’s solution and embedded in paraplast.
- Other examinations:
- After 2 weeks of premating treatment the F0 animals were mated to produce F1 generation pups. Mating pairs were from the same test group. Mating was discontinued as soon as sperm was detected in the vaginal smear. In dams food consumption was determined for gestation days 0 - 7, 7 - 14, 14 - 20 and lactation days 1 - 4.The pups were sexed and examined for macroscopically evident changes on PND 0. They were weighed on PND 1 and on PND 4. Their viability was recorded. At necropsy on PND 4, all pups were sacrificed and examined macroscopically for external and visceral findings.
- Statistics:
- Food consumption, body weight and body weight change: Simultaneous comparison of all dose groups with the control group using the DUNNETT-test (two-sided); Feces, grip strength of forelimbs and hindlimbs, landing foot-splay test, motor activity, clinical pathology parameters, weight parameters (except for urine color and turbidity): Non-parametric one-way analysis using KRUSKAL-WALLIS test (two-sided). If the resulting p-value was equal or less than 0.05, a pairwise comparison of each dose group with the control group was performed using WILCOXON-test (two-sided) for the equal medians;
Results and discussion
Results of examinations
- Details on results:
- CLINICAL SIGNS AND MORTALITY: No animal died prematurely in the present study. No test substance-related, adverse findings were noted. All animals of test group 1 (100 mg/kg bw/d) from study week 1 onwards and all animals of test groups 2-3 (300 and 1000 mg/kg bw/d) from study week 0 onwards showed blue discolored feces. During gestation all animals of test group 1 and 3 (100 and 1000 mg/kg bw/d) and 9 animals of test group 2 (300 mg/kg bw/d) showed blue discolored feces during gestation. Nine of nine animals of test group 1, nine of nine animals of test group 2 and seven of seven animals of test group 3 (100, 300 and 1000 mg/kg bw/d) showed blue discolored feces during lactation period.BODY WEIGHT AND WEIGHT GAIN:No changes of toxicological concern with regard to body weight parameters were observed during the entire study period. The body weight changes in males of test group 1 (100 mg/kg bw/d) from week 1 to 2 (71%) and in females of test group 3 (1000 mg/kg bw/d) during gestation days 0 to 7 (80%) were decreased.FOOD CONSUMPTION AND COMPOUND INTAKE: In males of test group 1 (100 mg/kg bw/d) food consumption was decreased from study week 1 to 2. Significantly decreased (up to 87%) food consumption during the entire gestation period in females of test group 3 (1000 mg/kg bw/d) was reported.HAEMATOLOGY: No treatment-related changes among hematological parameters were measured.CLINICAL CHEMISTRY: No treatment-related changes among clinical chemistry parameters were measured.URINALYSIS: No treatment-related changes among urinalyses parameters were measured.NEUROBEHAVIOUR:Deviations from "zero values" were obtained in several rats. However, as most findings were equally distributed between test-substance treated groups and controls, were without a dose-response relationship or occurred in single rats only, these observations were considered as incidental.ORGAN WEIGHTS:When compared to control group 0 (set to 100%), the mean absolute weights of following organs were significantly altered: liver (males / 100 mg/kg bw: 89%; males / 1000 mg/kg bw: 94%). When compared to control group 0 (set to 100%), none of the mean relative weights determined was significantly altered. The reduction in liver weight in males of test group 1 (100 mg/kg bw) and test group 3 (1000 mg/kg bw) is regarded to be incidental due to a missing altered relative organ weight, a missing dose response relationship and missing histopathologic findings that could explain the weight reduction. All other mean weight parameters did not show significant differences when compared to the control groups.GROSS PATHOLOGY: No test substance-related, adverse findings were noted. The only findings were: Discoloration of contents of glandular stomach, jejunum, colon and discoloration of the tongue. These findings are regarded to be treatment related but not adverse. The macroscopically observed dilation of the uterus in three animals of test group 3 (1000 mg/kg bw) are regarded to be related to the cycle and therefore no pathologic finding.HISTOPATHOLOGY: No signs of toxicity in the respective tissues were noted. The only findings were: Discoloration of contents of glandular stomach and jejunum, blue particles on surface of forestomach, cecum, rectum and discoloration of the tongue. These findings are regarded to be treatment related but not adverse. In the forestomach of all investigated animals bluish particles were located on top of the mucosal surface. The mucosa did not show any additional findings.OTHER FINDINGS:F1 PUPS:Clinical Examinations / Gross Findings: No test substance-related, adverse findings were noted.See chapter "Toxicity to reproduction" describing results on reproductive effects in more details.
Effect levels
open allclose all
- Dose descriptor:
- NOEL
- Effect level:
- 300 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: Based on reduced food consumption and decreased body weight change during gestation at 1000 mg/kg bw.
- Dose descriptor:
- NOEL
- Effect level:
- >= 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- other: Highest dose tested. No effects observed.
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Mean body weight change (g) of male animals (N = 10):
|
Week 0-1 |
Week 1-2 |
Week 2-3 |
Week 3-4 |
Test group 0 (0 mg/kg bw) |
26.1 |
21.6 |
14.6 |
15.3 |
SD |
5.69 |
3.99 |
4.95 |
4.11 |
Test group 1 (100 mg/kg bw) |
19.8 |
15.4* (71%) |
13.9 |
15.5 |
SD |
7.31 |
3.08 |
3.91 |
4.43 |
Test group 2 (300 mg/kg bw) |
25.1 |
17.4 |
12.9 |
16.2 |
SD |
8.25 |
6.37 |
7.88 |
4.91 |
Test group 3 (1000 mg/kg bw) |
24.5 |
18.4 |
16.4 |
15.9 |
SD |
7.80 |
4.12 |
5.09 |
3.60 |
Mean maternal body weight change during gestation (g):
|
Day of gestation |
||
0-7 |
7-14 |
14-20 |
|
Test group 0 (0 mg/kg bw) |
36.7 |
30.2 |
60.6 |
SD |
6.19 |
3.99 |
7.70 |
N |
9 |
9 |
9 |
Test group 1 (100 mg/kg bw) |
33.0 |
28.4 |
59.3 |
SD |
3.77 |
5.12 |
15.34 |
N |
9 |
9 |
9 |
Test group 2 (300 mg/kg bw) |
33.4 |
27.8 |
62.7 |
SD |
5.24 |
4.95 |
14.11 |
N |
9 |
9 |
9 |
Test group 3 (1000 mg/kg bw) |
29.4* (80%) |
24.4 |
55.1 |
SD |
8.16 |
8.89 |
21.82 |
N |
8 |
8 |
8 |
Mean male food consumption during premating (g/animal/day)
|
Week of study |
|
|
0-1 |
1-2 |
Test group 0 (0 mg/kg bw) |
22.1 |
22.9 |
SD |
1.46 |
1.11 |
N |
10 |
10 |
Test group 1 (100 mg/kg bw) |
21.1 |
20.9 |
SD |
1.28 |
1.29 |
N |
10 |
10 |
Test group 2 (300 mg/kg bw) |
21.4 |
21.9 |
SD |
1.81 |
2.11 |
N |
10 |
10 |
Test group 3 (1000 mg/kg bw) |
21.0 |
21.9 |
SD |
1.89 |
1.52 |
N |
10 |
10 |
Mean maternal food consumption during gestation (g/animal/day)
|
Day of gestation |
||
|
0-7 |
7-14 |
14-20 |
Test group 0 (0 mg/kg bw) |
19.3 |
22.0 |
22.8 |
SD |
1.18 |
1.93 |
1.46 |
N |
9 |
9 |
9 |
Test group 1 (100 mg/kg bw) |
18.3 |
20.5 |
21.2 |
SD |
1.06 |
1.26 |
1.35 |
N |
9 |
9 |
9 |
Test group 2 (300 mg/kg bw) |
19.1 |
21.6 |
22.2 |
SD |
1.17 |
1.12 |
0.88 |
N |
9 |
9 |
9 |
Test group 3 (1000 mg/kg bw) |
17.0* (88%) |
19.1* (87%) |
20.3* (89%) |
SD |
2.27 |
2.69 |
2.33 |
N |
8 |
8 |
8 |
*p ≤ 0.05
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.